RBC Bioscience Corporation (TPEX:6848)
18.60
-1.45 (-7.23%)
Nov 20, 2026, 1:48 PM CST
RBC Bioscience Revenue
RBC Bioscience had revenue of 108.59M TWD in the half year ending June 30, 2026, a decrease of -2.25%. This brings the company's total for the last twelve months to 209.59M, down -0.57% year-over-year. In the year 2025, RBC Bioscience had annual revenue of 219.71M with 7.05% growth. That makes RBC Bioscience the 39,207th largest company in the world by revenue and 2,034th in Taiwan.
Revenue (ttm)
209.59M
Revenue Growth
-0.57%
P/S Ratio
1.27
Revenue / Employee
4.19M
Employees
50
Market Cap
265.49M
Revenue by Geography
- Europe 146.34M 66.6%
- Asia 31.69M 14.4%
- Africa 14.51M 6.6%
- Taiwan 14.31M 6.5%
- America 12.84M 5.8%
- Other Countries 21.00K 0.0%
Fiscal year ended Dec 31, 2025 See the full RBC Bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 219.71M | 14.46M | 7.05% |
| Dec 31, 2024 | 205.25M | 32.78M | 19.01% |
| Dec 31, 2023 | 172.47M | -1.42M | -0.82% |
| Dec 31, 2022 | 173.89M | -77.29M | -30.77% |
| Dec 31, 2021 | 251.18M | -323.98M | -56.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| GeneReach Biotechnology | 241.13M |
| NatureWise Biotech & Medicals | 174.62M |
| Visgeneer | 170.72M |
| Feng Chi Biotech | 156.99M |
| Vectorite Biomedical | 54.81M |
| Neith | 32.29M |